

## Recombinant Human Interleukin-35/IL-35 Protein (Fc Tag)

**Catalog No.** PKSH031988

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

<b>Synonyms</b>	CLMF;IL-12A;IL-35;Interleukin-35;NFSK;NKSF1;P35
<b>Species</b>	Human
<b>Expression Host</b>	HEK293 Cells
<b>Sequence</b>	Met 1-Lys 229
<b>Accession</b>	Q14213&P29459
<b>Calculated Molecular Weight</b>	73.4 kDa
<b>Tag</b>	C-hFc
<b>Bioactivity</b>	Measured by its ability to bind biotinylated human IL6RB-Fch in a functional ELISA.

### Properties

<b>Purity</b>	> 85 % as determined by reducing SDS-PAGE.
<b>Endotoxin</b>	< 1.0 EU per µg of the protein as determined by the LAL method.
<b>Storage</b>	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
<b>Shipping</b>	This product is provided as lyophilized powder which is shipped with ice packs.
<b>Formulation</b>	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
<b>Reconstitution</b>	Please refer to the printed manual for detailed information.

### Data



> 85 % as determined by reducing SDS-PAGE.

### Background

The novel Ebi3-IL-12α heterodimeric cytokine has been designated interleukin-35 (IL-35), is a member IL12 family cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a

### For Research Use Only

heterodimeric protein composed of IL-12&alpha, (P35) and IL-27&beta, chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4(+)CD25(+)Foxp3(+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory cytokine, along with TGFbeta cytokine. IL-35 is a cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.